Halozyme jumps as Benchmark hikes price target to $90 on guidance confidence
Halozyme Therapeutics shares are rising after a fresh analyst price-target increase reinforced the bull case for its royalty-led growth profile. Benchmark lifted its target to $90 from $75 while keeping a Buy rating following strong results and forward guidance.
1. What’s moving the stock today
Halozyme Therapeutics (HALO) is trading higher today as investors react to a new bullish analyst note. Benchmark raised its price target to $90 from $75 and kept a Buy rating, citing strong results and positive forward guidance, helping lift sentiment around the stock in today’s session.
2. Why the note matters for HALO’s setup
Halozyme’s investment narrative is tightly linked to the durability and growth of ENHANZE-enabled royalty streams and the company’s ability to extend its long-run opportunity set. The latest target increase effectively signals confidence that royalty momentum and guidance visibility remain intact, supporting a higher valuation framework for the shares.
3. The fundamentals investors are anchoring on
In its most recent full-year update, Halozyme reported record 2025 total revenue of about $1.4 billion and record royalty revenue of $868 million, and it reiterated 2026 guidance that implies another step-up in scale. The company’s reiterated 2026 ranges include total revenue of $1.710–$1.810 billion and non-GAAP diluted EPS of $7.75–$8.25, with management also projecting royalty revenue to exceed $1 billion in 2026—metrics that continue to underpin bullish targets.